Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trialResearch in context

Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trialResearch in context

Summary: Background: Tau pathology correlates with and predicts clinical decline in Alzheimer’s disease. Approved tau-targeted therapies are not available. Methods: ADAMANT, a 24-month randomised, placebo-controlled, parallel-group, double-blinded, multicenter, Phase 2 clinical trial (EudraCT2015-0...

Full description

Bibliographic Details
Main Authors: Nicholas C. Cullen, Petr Novak, Duygu Tosun, Branislav Kovacech, Jozef Hanes, Eva Kontsekova, Michal Fresser, Stefan Ropele, Howard H. Feldman, Reinhold Schmidt, Bengt Winblad, Norbert Zilka
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:EBioMedicine
Subjects:
Tau
Alzheimer’s disease
Immunotherapy
Machine learning
Post-hoc analysis
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396423004899

Internet

http://www.sciencedirect.com/science/article/pii/S2352396423004899

Similar Items